share_log

Does Loctek Ergonomic Technology (SZSE:300729) Deserve A Spot On Your Watchlist?

Does Loctek Ergonomic Technology (SZSE:300729) Deserve A Spot On Your Watchlist?

Loctek 人体工程学技术(深圳证券交易所:300729)值得在您的关注清单上占有一席之地吗?
Simply Wall St ·  03/12 02:20

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.

许多投资者,尤其是那些没有经验的投资者,通常会购买有好故事的公司的股票,即使这些公司亏损。有时,这些故事可能会给投资者的思想蒙上阴影,导致他们用自己的情感进行投资,而不是根据良好的公司基本面的优点进行投资。虽然资金充足的公司可能会遭受多年的损失,但它最终需要创造利润,否则投资者将继续前进,公司将萎缩。

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Loctek Ergonomic Technology (SZSE:300729). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

尽管处在科技股蓝天投资时代,但许多投资者仍然采取更传统的策略:购买乐泰人体工程学科技(深圳证券交易所代码:300729)等盈利公司的股票。尽管利润不是投资时应考虑的唯一指标,但值得表彰能够持续生产利润的企业。

How Fast Is Loctek Ergonomic Technology Growing?

Loctek 人体工程学技术的发展速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, Loctek Ergonomic Technology has grown EPS by 32% per year, compound, in the last three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.

如果你认为市场的效率甚至含糊不清,那么从长远来看,你预计公司的股价将遵循其每股收益(EPS)的结果。因此,有很多投资者喜欢购买每股收益不断增长的公司的股票。令人印象深刻的是,乐泰人体工程学技术在过去三年中每股收益复合增长了32%。一般来说,如果一家公司能跟上步伐,我们会这么说 那个 有点像增长,股东们会喜气洋洋。

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Loctek Ergonomic Technology remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 16% to CN¥3.6b. That's encouraging news for the company!

仔细考虑收入增长和息税前收益(EBIT)利润率有助于为近期利润增长的可持续性提供信息。乐泰人体工程学技术的息税前利润率与去年相比基本保持不变,但该公司应该很高兴地报告其收入增长了16%,达到36亿元人民币。这对公司来说是个令人鼓舞的消息!

The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.

下图显示了该公司的收入和收入随着时间的推移是如何发展的。要了解更多细节,请点击图片。

earnings-and-revenue-history
SZSE:300729 Earnings and Revenue History March 12th 2024
SZSE: 300729 2024 年 3 月 12 日的收益和收入历史记录

You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Loctek Ergonomic Technology's future profits.

你开车时不要注视后视镜,因此你可能会对这份免费报告更感兴趣,该报告显示了分析师对乐泰人体工程学技术未来利润的预测。

Are Loctek Ergonomic Technology Insiders Aligned With All Shareholders?

Loctek 人体工程学技术内部人士是否与所有股东保持一致?

It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Loctek Ergonomic Technology followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. Holding CN¥440m worth of stock in the company is no laughing matter and insiders will be committed in delivering the best outcomes for shareholders. This would indicate that the goals of shareholders and management are one and the same.

可以说,看到公司领导者将资金投入到危险之中真是令人高兴,因为这提高了企业经营者与其真正所有者之间激励措施的一致性。Loctek 人体工程学技术的追随者会感到欣慰的是,内部人士拥有大量资本,可以使他们的最大利益与更广泛的股东群体保持一致。持有该公司价值4.4亿元人民币的股票不是笑话,内部人士将致力于为股东带来最佳业绩。这将表明股东和管理层的目标是相同的。

Should You Add Loctek Ergonomic Technology To Your Watchlist?

您是否应该将 Loctek 人体工程学技术添加到您的关注列表中?

For growth investors, Loctek Ergonomic Technology's raw rate of earnings growth is a beacon in the night. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. You still need to take note of risks, for example - Loctek Ergonomic Technology has 4 warning signs (and 1 which is potentially serious) we think you should know about.

对于成长型投资者来说,乐泰人体工程学技术的原始收益增长率是夜间的灯塔。这种每股收益增长率是该公司应该引以为豪的,因此,内部人士持有相当一部分股票也就不足为奇了。从优点来看,稳健的每股收益增长以及与股东保持一致的公司内部人士将表明该业务值得进一步研究。您仍然需要注意风险,例如,Loctek 人体工程学技术有 4 个警告标志(其中一个可能很严重),我们认为您应该知道。

Although Loctek Ergonomic Technology certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with insider buying, then check out this handpicked selection of Chinese companies that not only boast of strong growth but have also seen recent insider buying..

尽管乐泰人体工程学技术看起来确实不错,但如果内部人士买入股票,它可能会吸引更多的投资者。如果你想看看有内幕买入的公司,那就看看这些精心挑选的中国公司,这些公司不仅拥有强劲的增长,而且最近也出现了内幕买盘。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

请注意,本文中讨论的内幕交易是指相关司法管辖区内应报告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发